Osteoporosis Management in Women (OMW) is a Medicare Advantage HEDIS measure focused on women ages 67-85 who have experienced a qualifying fracture. To close this care opportunity, the member must receive either a bone mineral density (BMD) test or an osteoporosis medication within 180 days (six months) after the fracture. Because the follow-up window is time-limited, early identification, outreach, and coordination can make a meaningful difference in helping members complete recommended post-fracture care. 

What the measure looks at: 

• Eligible population: Women ages 67-85 who had a qualifying fracture during the measure intake period.
• Timely follow-up: A BMD test or osteoporosis treatment must occur within 180 days (six months) of the fracture.
• Treatments that may meet the measure include bisphosphonates and other osteoporosis agents such as Abaloparatide, Denosumab, Raloxifene, Romosozumab, Teriparatide, and Zoledronic Acid (Reclast), when administered and coded appropriately.
• Fractures of the finger, toe, face, and skull are not included in the measure. 

Why early action matters: 

OMW gaps can become non-impactable quickly if the 180-day window has passed. For this reason, reviewing OMW reports as soon as they are available and acting on newly identified fractures to accomplish ordering and completing scans within the 180-day (about six months) timeframe. As of July 2026, newly identified fracture episodes may impact MY 2027 performance, so early action now can help position practices for the next measurement year and avoid losing valuable follow-up time once 2027 begins. 

How providers can help close OMW care opportunities: 

• Review monthly OMW reports and prioritize members with approaching intervention due dates.
• Confirm whether the member has already had a qualifying BMD test or osteoporosis treatment that may not yet be reflected in claims or supplemental data.
• Place and communicate BMD scan orders promptly when a scan is needed.
• Document and code qualifying osteoporosis treatment accurately, including injectable therapies when applicable.
• Coordinate outreach early, especially when members need assistance scheduling or completing imaging appointments.